search
Back to results

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

Primary Purpose

Oral Leukoplakia

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Lozenge Intake
Sponsored by
University of Medicine and Dentistry of New Jersey
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Oral Leukoplakia focused on measuring oral leukoplakia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Patients with oral leukoplakia without evidence of active infections in the mouth will be invited to participate in this study. Patients must currently consume no more than 3 cups of tea a day, not be taking large doses of vitamin A or its derivatives (more than 25,000 units), selenium, or beta-carotene. Additionally, patients must not participate in this study if they are allergic to caffeine, have GI ulcers, are pregnant, or have had previous invasive mouth cancer.

Sites / Locations

  • The Cancer Institute of New Jersey

Outcomes

Primary Outcome Measures

To assess the effect of green tea lozenge versus placebo on the prevalence, size, and histologic severity of oral leukoplakia.

Secondary Outcome Measures

Additionally, we will correlate the changes in oral leukoplakia with levels of tea polyphenols in saliva and in biopsied lesions; DNA content in leukoplakia cells obtained from buccal scrapings; and proliferation index, apoptotic index, and expression of

Full Information

First Posted
September 12, 2005
Last Updated
December 10, 2009
Sponsor
University of Medicine and Dentistry of New Jersey
search

1. Study Identification

Unique Protocol Identification Number
NCT00176566
Brief Title
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
Official Title
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2009
Overall Recruitment Status
Terminated
Why Stopped
Transitioned into a national study through ECOG
Study Start Date
September 2003 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
November 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Medicine and Dentistry of New Jersey

4. Oversight

5. Study Description

Brief Summary
You have been asked to participate in this research study because you have or may have oral leukoplakia. Oral leukoplakia is described as a white patch or plaque on the oral mucosa (mouth) that will not rub off and cannot be removed by scraping, reversed by elimination of obvious irritants (things that cause redness and/or swelling) such as dentures (artificial replacment for missing teeth), or lesions as described that are diagnosed by your dentist.
Detailed Description
Since oral leukoplakia may precede the development of cancer, using agents that may prevent cancer, called chemoprevention, may be useful. The purpose of this study is to determine whether taking a green tea preparation may have effects on your leukoplakia. It is hoped that these effects may reduce the subsequent risk of cancer in or around the area of leukoplakia. To assess for these effects, samples of the lining of your mouth will be obtained, and they will be analyzed looking for certain features (biomarkers).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oral Leukoplakia
Keywords
oral leukoplakia

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Lozenge Intake
Intervention Description
of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
Primary Outcome Measure Information:
Title
To assess the effect of green tea lozenge versus placebo on the prevalence, size, and histologic severity of oral leukoplakia.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Additionally, we will correlate the changes in oral leukoplakia with levels of tea polyphenols in saliva and in biopsied lesions; DNA content in leukoplakia cells obtained from buccal scrapings; and proliferation index, apoptotic index, and expression of
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patients with oral leukoplakia without evidence of active infections in the mouth will be invited to participate in this study. Patients must currently consume no more than 3 cups of tea a day, not be taking large doses of vitamin A or its derivatives (more than 25,000 units), selenium, or beta-carotene. Additionally, patients must not participate in this study if they are allergic to caffeine, have GI ulcers, are pregnant, or have had previous invasive mouth cancer.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Goodin, PharmD
Organizational Affiliation
Rutgers, The State University of New Jersey
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Cancer Institute of New Jersey
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

We'll reach out to this number within 24 hrs